Oncoinvent A

Oncoinvent A EBIT Margin

The EBIT Margin (Operating Margin) of Oncoinvent A (ONCIN.OL) as of Nov 7, 2026 is -564.07 %. In the previous year, EBIT Margin (Operating Margin) was -17,834.20 % — a change of -96.84% (higher).

EBIT Margin

-564.07 %

YoY

-96.84%

Last updated:

EBIT Margin (Operating Margin) of Oncoinvent A is 2025 -564.07 % . EBIT Margin (Operating Margin) of Oncoinvent A was 2024 -17,834.20 % . It decreases by -96.84% higher compared to the previous year.

For Oncoinvent A, the operating (EBIT) margin of -564.1% is up versus -40,628.2% a few years ago.

The Oncoinvent A EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-8,331.43 NOK
Jan 1, 2019
-2,296.34 NOK
Jan 1, 2020
-43,442.76 NOK
Jan 1, 2021
-40,628.17 NOK
Jan 1, 2022
-78,569.41 NOK
Jan 1, 2023
-54,186.16 NOK
Jan 1, 2024
-17,834.20 NOK
Jan 1, 2025
-564.07 NOK
The Oncoinvent A EBIT Margin history
YEAREBIT MarginYoY
-564.07 %-96.84%
-17,834.20 %-67.09%
-54,186.16 %-31.03%
-78,569.41 %+93.39%
-40,628.17 %-6.48%
-43,442.76 %+1,791.83%
-2,296.34 %-72.44%
-8,331.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncoinvent A Stock analysis

What does Oncoinvent A do? Oncoinvent ASA is a radiopharmaceutical company based in Oslo, Norway, operating within the Health Care sector. Listed on 13 December 2024, the firm employs 46 people and focuses on developing alpha-emitting radiotherapeutics for cancer patients. Its primary product, Radspherin, is an alpha-emitting radioactive microsphere therapy designed to treat metastatic cancers in body cavities. This suspension of calcium carbonate microspheres labelled with Radium-224 targets residual micro-metastases on intracavitary surfaces and in liquids after surgery, aiming to spare deeper organs from harmful radiation doses. Oncoinvent A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncoinvent A stock

EBIT Margin (Operating Margin) of Oncoinvent A is -564.07 % in 2025.

EBIT Margin (Operating Margin) of Oncoinvent A changed from -17,834.20 % to -564.07 %, representing a -96.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Oncoinvent A since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Oncoinvent A with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Oncoinvent A

All Key Metrics — Oncoinvent A